



THE PRIMARY CARE COMPANION FOR CNS DISORDERS

Supplementary Material

Article Title: Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial

Author(s): Marilyn C. Olson, PhD; Alejandra Maciel; Jean Francois Gariepy, PhD; Ali Cullors; Juan-Sebastian Saldivar, MD; David Taylor, PharmD; Joel Centeno; Jorge A. Garces, PhD; and Sandeep Vaishnavi, MD, PhD

DOI Number: <https://doi.org/10.4088/PCC.16m02036>

List of Supplementary Material for the article

1. [Table 1](#)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial

Table 1. Distribution of CYP450 Phenotypes

Gene	Phenotype	Experimental Group (%)	Control Group (%)	P Value ^a
CYP1A2 ^b	Ultra-rapid	83.2	81.5	0.91
	Extensive	9.6	11.1	
	Intermediate	7.2	7.4	
	Poor	0	0	
CYP2C9	Ultra-rapid	0	0	1.00
	Extensive	67.4	67.8	
	Intermediate	32.6	32.2	
	Poor	0	0	
CYP2C19	Ultra-rapid	30.3	27.1	0.58
	Extensive	41.6	39.0	
	Intermediate	27.0	30.5	
	Poor	1.1	3.4	
CYP2D6	Ultra-rapid	1.7	6.8	0.17
	Extensive	79.2	81.4	
	Intermediate	9.6	6.8	
	Poor	9.6	5.1	
CYP3A4	Ultra-rapid	0	0	0.63
	Extensive	88.8	91.5	
	Intermediate	11.2	8.5	
	Poor	0	0	
CYP3A5	Ultra-rapid	0	0	0.63
	Extensive	3.4	1.7	
	Intermediate	15.2	20.3	
	Poor	81.5	78.0	

^aTwo-sided Fisher's Exact Test, using only observations with known phenotype.

^b16 subjects with unknown phenotype for CYP1A2 gene (Experimental=11, Control=5) are excluded from this table